Cellular and Functional Characterization of Immunoresistant Human Glioma Cell Clones Selected With Alloreactive Cytotoxic T Lymphocytes Reveals Their Up-regulated Synthesis of Biologically Active TGF-β
暂无分享,去创建一个
[1] T. Witham,et al. Expression of a soluble transforming growth factor-β (TGFβ) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcomain vivo , 2003, Journal of Neuro-Oncology.
[2] W. Franklin,et al. Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses , 1992, In Vitro Cellular & Developmental Biology - Animal.
[3] M. Varella‐Garcia,et al. Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization. , 2006, Cancer genetics and cytogenetics.
[4] C. Kruse,et al. Subsets within alloreactive CTL (aCTL) exhibit upregulated proinflammatory cytokine secretion: aCTL response to coincubation with irrelevant and relevant parental and immunoresistant (IR) gliomas , 2006 .
[5] N. Bercovici,et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate , 2006, Cancer Immunology, Immunotherapy.
[6] J. Massagué,et al. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. , 2005, Cancer cell.
[7] Jack T. Lin,et al. TGF-β1 Uses Distinct Mechanisms to Inhibit IFN-γ Expression in CD4+ T Cells at Priming and at Recall: Differential Involvement of Stat4 and T-bet1 , 2005, The Journal of Immunology.
[8] Erwin G. Van Meir,et al. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. , 2005, Neuro-oncology.
[9] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[10] S. Ferrone,et al. Immune Selection of Hot-Spot β2-Microglobulin Gene Mutations, HLA-A2 Allospecificity Loss, and Antigen-Processing Machinery Component Down-Regulation in Melanoma Cells Derived from Recurrent Metastases following Immunotherapy1 , 2005, The Journal of Immunology.
[11] Jack T. Lin,et al. TGF-beta 1 uses distinct mechanisms to inhibit IFN-gamma expression in CD4+ T cells at priming and at recall: differential involvement of Stat4 and T-bet. , 2005, Journal of immunology.
[12] B. Eliceiri,et al. Glioma cell integrin expression and their interactions with integrin antagonists: Research Article. , 2005, Cancer therapy.
[13] I. Egorov. Mouse models of efficient and inefficient anti-tumor immunity, with emphasis on minimal residual disease and tumor escape , 2005, Cancer Immunology, Immunotherapy.
[14] R. McCarron,et al. Mechanisms by which human gliomas may escape cellular immune attack , 2005, Acta Neurochirurgica.
[15] M. Weller,et al. RNA Interference Targeting Transforming Growth Factor-β Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates Tumorigenicity In vivo , 2004, Cancer Research.
[16] J. Modiano,et al. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells. , 2004, Clinical immunology.
[17] L. Gerschenson,et al. Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors. , 2004, Neuro-oncology.
[18] T. Witham,et al. Expression of a Soluble Transforming Growth Factor-β (TGFβ) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo , 2004, Journal of Neuro-Oncology.
[19] Chulhee Choi,et al. Fas Engagement Increases Expression of Interleukin-6 in Human Glioma Cells , 2004, Journal of Neuro-Oncology.
[20] Barry H. Smith,et al. Ultrastructural features of the lymphocyte-stimulated halos produced by human glioma-derived cells in vitro , 2004, Journal of Neuro-Oncology.
[21] C. Chao,et al. Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling. , 2003, The Biochemical journal.
[22] F. Faure,et al. Exosomes bearing HLA-G are released by melanoma cells. , 2003, Human immunology.
[23] Steven A. Rosenberg,et al. Cell Transfer Therapy for Cancer: Lessons from Sequential Treatments of a Patient With Metastatic Melanoma , 2003, Journal of immunotherapy.
[24] D. B. Paul,et al. Human Alloreactive CTL Interactions with Gliomas and with Those Having Upregulated HLA Expression from Exogenous IFN-γ or IFN-γ Gene Modification , 2003 .
[25] A. Belldegrun,et al. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes. , 2003, International journal of oncology.
[26] D. B. Paul,et al. Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-gamma or IFN-gamma gene modification. , 2003, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[27] Pedro Romero,et al. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity , 2002, Oncogene.
[28] M. Simon,et al. Antigen-Dependent Release of IFN-γ by Cytotoxic T Cells Up-Regulates Fas on Target Cells and Facilitates Exocytosis-Independent Specific Target Cell Lysis , 2002, The Journal of Immunology.
[29] M. Weller,et al. A Functional Role of HLA-G Expression in Human Gliomas: An Alternative Strategy of Immune Escape1 , 2002, The Journal of Immunology.
[30] F. Garrido,et al. Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy. , 2002, Seminars in cancer biology.
[31] C. Kruse,et al. Effects of IFN-gamma and interleukin-1beta on major histocompatibility complex antigen and intercellular adhesion molecule-1 expression by 9L gliosarcoma: relevance to its cytolysis by alloreactive cytotoxic T lymphocytes. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[32] Chun-Ming Lin,et al. Activated human CD4+ T cells induced by dendritic cell stimulation are most sensitive to transforming growth factor-beta: implications for dendritic cell immunization against cancer. , 2002, Clinical immunology.
[33] C. Kruse,et al. Strategies using the immune system for therapy of brain tumors. , 2001, Hematology/oncology clinics of North America.
[34] K. Kiura,et al. Generation of cytotoxic T lymphocytes against autologous lung cancer cells resistant to apoptosis. , 2001, Anticancer research.
[35] K. Kiura,et al. Tumor-specific cytotoxic T lymphocyte responses against chondrosarcoma with HLA haplotype loss restricted by the remaining HLA class I allele. , 2001, Biochemical and biophysical research communications.
[36] X. Xu,et al. Fas-induced expression of chemokines in human glioma cells: involvement of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. , 2001, Cancer research.
[37] B. Weinshenker,et al. Genetic variation in the transforming growth factor β1 gene in multiple sclerosis , 2001, Journal of Neuroimmunology.
[38] R. Merchant,et al. IL-6 Secretion by a Rat T9 Glioma Clone Induces a Neutrophil-Dependent Antitumor Response with Resultant Cellular, Antiglioma Immunity1 , 2001, The Journal of Immunology.
[39] Carol A. Kruse,et al. Cytotoxic T-Lymphocytes Reactive to Patient Major Histocompatibility Complex Proteins for Therapy of Brain Tumors , 2001 .
[40] R. Flavell,et al. Cutting Edge: TGF-β Inhibits Th Type 2 Development Through Inhibition of GATA-3 Expression , 2000, The Journal of Immunology.
[41] D. B. Paul,et al. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy. , 2000, Cancer research.
[42] M. Simon,et al. Cytotoxic T Cells Specifically Induce Fas on Target Cells, Thereby Facilitating Exocytosis-Independent Induction of Apoptosis1 , 2000, The Journal of Immunology.
[43] S. Rhodes,et al. Identification of transforming growth factor‐β1‐binding protein overexpression in carmustine‐resistant glioma cells by MRNA differential display , 2000 .
[44] L. Salford,et al. Expression of TGF‐β isoforms, TGF‐β receptors, and SMAD molecules at different stages of human glioma , 2000 .
[45] D. Hunt,et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens , 2000, Cancer Immunology, Immunotherapy.
[46] R. Flavell,et al. Abrogation of TGFβ Signaling in T Cells Leads to Spontaneous T Cell Differentiation and Autoimmune Disease , 2000 .
[47] R. Flavell,et al. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. , 2000, Immunity.
[48] L. Salford,et al. Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. , 2000, International journal of cancer.
[49] T. Roszman,et al. Immune defects observed in patients with primary malignant brain tumors , 1999, Journal of Neuroimmunology.
[50] R. Offringa,et al. Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein , 1999, The Journal of experimental medicine.
[51] J. Dausset,et al. HLA-G inhibits the allogeneic proliferative response. , 1999, Journal of reproductive immunology.
[52] A. Régnault,et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. , 1999, Journal of immunology.
[53] H. Rammensee,et al. TGF‐β‐independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells , 1999 .
[54] H. Rammensee,et al. TGF-beta-independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells. , 1999, European Journal of Immunology.
[55] J. Laterra,et al. IL-10 gene transfer to intracranial 9L glioma: tumor inhibition and cooperation with IL-2 , 1998, Journal of Neuroimmunology.
[56] Charles B. Wilson,et al. Primary central nervous system tumors: Advances in knowledge and treatment , 1998, CA: a cancer journal for clinicians.
[57] J. Westwick,et al. Chemokines: understanding their role in T-lymphocyte biology. , 1998, The Biochemical journal.
[58] T. Ohnishi,et al. In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. , 1998, Biochemical and biophysical research communications.
[59] J. Stears,et al. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2 , 1997, Cancer Immunology, Immunotherapy.
[60] C. Kruse,et al. Artificial‐capillary‐systemdevelopment of human alloreactive cytotoxic T‐lymphocytes that lyse brain tumour , 1997 .
[61] P. Walker,et al. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. , 1997, Journal of immunology.
[62] C. Kruse,et al. Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours. , 1997, Biotechnology and applied biochemistry.
[63] S. Coons,et al. Dichotomy of astrocytoma migration and proliferation , 1996, International journal of cancer.
[64] D. Mercola,et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[65] F. Marincola,et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. , 1996, Journal of the National Cancer Institute.
[66] B. Drénou,et al. The HLA-G gene is expressed at a low mRNA level in different human cells and tissues. , 1994, Human immunology.
[67] F. Marincola,et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. , 1994, Journal of immunology.
[68] K. Stefansson,et al. Inhibition of T cell activation by the extracellular matrix protein tenascin. , 1994, Journal of immunology.
[69] T. Libermann,et al. Coexpression of Interleukin-1β and Interleukin-6 in Human Brain Tumors , 1994 .
[70] T. Libermann,et al. Coexpression of interleukin-1 beta and interleukin-6 in human brain tumors. , 1994, Neurosurgery.
[71] L. Clement,et al. Heterogeneous mechanisms of human cytotoxic T lymphocyte generation. II. Differential effects of IL-6 on the helper cell-independent generation of CTL from CD8+ precursor subpopulations. , 1993, Journal of immunology.
[72] A. Gritzapis,et al. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine‐activated killer cell function in patients with breast cancer , 1993, Cancer.
[73] U. Bogdahn,et al. The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. , 1993, Journal of neurosurgery.
[74] J. Murray,et al. Linkage localization of TGFB2 and the human homeobox gene HLX1 to chromosome 1q. , 1993, Genomics.
[75] Erwin G. Van Meir,et al. Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system. , 1992, Cancer research.
[76] D. Constam,et al. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. , 1992, Journal of immunology.
[77] H. Young,et al. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta. , 1991, Journal of immunology.
[78] P. Nowell,et al. Growth factor requirements of childhood acute T-lymphoblastic leukemia: correlation between presence of chromosomal abnormalities and ability to grow permanently in vitro. , 1991, Blood.
[79] Erwin G. Van Meir,et al. Human glioblastoma cells release interleukin 6 in vivo and in vitro. , 1990, Cancer research.
[80] S. Rosenberg,et al. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures. , 1990, Journal of immunology.
[81] K. Frei,et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. , 1989, Journal of immunology.
[82] G. Moore,et al. Interleukin‐2—activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro , 1989, Cancer.
[83] R. Supino,et al. Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistance , 1989, International journal of cancer.
[84] T. Espevik,et al. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha , 1987, The Journal of experimental medicine.
[85] L. Muul,et al. In vitro studies on the cell-mediated immune response to human brain tumors. II. Leukocyte-induced coats of glycosaminoglycan increase the resistance of glioma cells to cellular immune attack. , 1984, Journal of immunology.
[86] M. Gately,et al. Lymphoid cell-glioma cell interaction enhances cell coat production by human gliomas: novel suppressor mechanism. , 1983, Science.
[87] P. Medawar. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. , 1948, British journal of experimental pathology.